ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
1. **NAME OF THE VETERINARY MEDICINAL PRODUCT**

Acticam 5 mg/ml solution for injection for dogs and cats.

2. **QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each ml contains:

**Active substance:**
Meloxicam 5 mg.

**Excipients:**
Ethanol, anhydrous 150 mg.

For the full list of excipients, see section 6.1.

3. **PHARMACEUTICAL FORM**

Solution for injection.
A clear yellow solution.

4. **CLINICAL PARTICULARS**

4.1 **Target species**

Dogs and cats.

4.2 **Indications for use, specifying the target species**

**Dogs:**
Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders. Reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery.

**Cats:**
Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.

4.3 **Contraindications**

Do not use in pregnant or lactating animals.
Do not use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.
Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
Do not use in animals less than 6 weeks of age nor in cats of less than 2 kg.
Do not use an oral follow-up therapy using meloxicam or other NSAIDs in cats, as no safe dosage for repeated oral administration has been established.

4.4 **Special warnings for each target species**

For post-operative pain relief in cats, safety has only been documented after thiopental/halothane anaesthesia.
4.5 Special precautions for use

Special precautions for use in animals

If side effects occur, treatment should be discontinued. Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

Accidental self-injection may give rise to pain. People with known hypersensitivity to meloxicam should avoid contact with the veterinary medicinal product. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

4.6 Adverse reactions (frequency and seriousness)

Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure have occasionally been reported. In very rare cases elevated liver enzymes have been reported. In dogs, in very rare cases, haemorrhagic diarrhoea, haematemesisis and gastrointestinal ulceration have been reported. In dogs, these side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal. In very rare cases anaphylactoid reactions may occur and should be treated symptomatically.

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

4.7 Use during pregnancy, lactation or lay

The safety of the veterinary medicinal product has not been established during pregnancy and lactation (see 4.3).

4.8 Interaction with other medicinal products and other forms of interaction

Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Acticam must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Concurrent administration of potential nephrotoxic drugs should be avoided. In animals at anaesthetic risk (e.g. aged animals) intravenous or subcutaneous fluid therapy during anaesthesia should be taken into consideration. When anaesthesia and NSAID are concomitantly administered, a risk for renal function cannot be excluded. Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacokinetic properties of the products used previously.
4.9 Amounts to be administered and administration route

**Dogs:**
Musculo-skeletal disorders:
Single subcutaneous injection at a dosage of 0.2 mg meloxicam/kg body weight (i.e. 0.4 ml/10 kg body weight).

Reduction of post-operative pain (over a period of 24 hours):
Single intravenous or subcutaneous injection at a dosage of 0.2 mg meloxicam/kg body weight (i.e. 0.4 ml/10 kg body weight) before surgery, for example at the time of induction of anaesthesia.

**Cats:**
Reduction of post-operative pain:
Single subcutaneous injection at a dosage of 0.3 mg meloxicam/kg body weight (i.e. 0.06 ml/kg body weight) before surgery, for example at the time of induction of anaesthesia.

Particular care should be taken with regard to the accuracy of dosing.

Avoid introduction of contamination during use.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
In the case of over dosage symptomatic treatment should be initiated.

4.11 Withdrawal period(s)
Not applicable.

5. PHARMACOLOGICAL PROPERTIES

Pharmacotherapeutic group: Antiinflammatory and antirheumatic products, non-steroids (oxicams)
ATCvet code: QM01AC06

5.1 Pharmacodynamic properties
Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class, which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. In vitro and in vivo studies demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1).

5.2 Pharmacokinetic particulars

**Absorption**
Following subcutaneous administration, meloxicam is completely bioavailable and maximal mean plasma concentrations of 0.73 μg/ml in dogs and 1.1 μg/ml in cats were reached approximately 2.5 hours and 1.5 hours post administration, respectively.

**Distribution**
There is a linear relationship between the dose administered and plasma concentration observed in the therapeutic dose range in dogs. More than 97% of meloxicam is bound to plasma proteins. The volume of distribution is 0.3 l/kg in dogs and 0.09 l/kg in cats.
Metabolism
In dogs, meloxicam is predominantly found in plasma and is also a major biliary excretion product whereas urine contains only traces of the parent compound. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive.

Elimination
Meloxicam is eliminated with a half-life of 24 hours in dogs and 15 hours in cats. Approximately 75% of the administered dose is eliminated via faeces and the remainder via urine.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients
Ethanol anhydrous
Poloxamer 188
Glycofurol
Meglumine
Glycine
Sodium Chloride
Sodium Hydroxide
Water for injection

6.2 Major incompatibilities
In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

6.3 Shelf life
Shelf-life of the veterinary medicinal product as packaged for sale: 3 years. Shelf-life after first opening the immediate packaging: 28 days.

6.4 Special precautions for storage
This veterinary medicinal product does not require any special storage conditions.

6.5 Nature and composition of immediate packaging
Colourless type I glass injection vial of 10 ml, closed with a grey EPDM rubber stopper and sealed with a flip off aluminium seal.

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
7. **MARKETING AUTHORISATION HOLDER**

Ecuphar NV  
Legeweg 157-i  
B-8020 Oostkamp  
Belgium

8. **MARKETING AUTHORISATION NUMBER(S)**

EU/2/08/088/004

9. **DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 09/12/2008  
Date of last renewal: 09/12/2013

10. **DATE OF REVISION OF THE TEXT**

...

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/).

**PROHIBITION OF SALE, SUPPLY AND/OR USE**

Not applicable.
ANNEX II

A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. STATEMENT OF THE MRLs
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer responsible for batch release

Ecuphar NV
Legeweg 157-i
B-8020 Oostkamp
Belgium

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Veterinary medicinal product subject to prescription.

C. STATEMENT OF THE MRLs

Not applicable.
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
PARTICULARS TO APPEAR ON THE OUTER PACKAGE

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Acticam 5 mg/ml solution for injection for dogs and cats. Meloxicam.

2. STATEMENT OF ACTIVE SUBSTANCES

Meloxicam 5 mg/ml.

3. PHARMACEUTICAL FORM

Solution for injection.

4. PACKAGE SIZE

10 ml.

5. TARGET SPECIES

6. INDICATION(S)

7. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.

8. WITHDRAWAL PERIOD(S)

9. SPECIAL WARNING(S), IF NECESSARY

Do not use in pregnant or lactating animals.
10. **EXPIRY DATE**

EXP {month/year}
Shelf-life after first opening the container: 28 days.
Once broached use by ...

11. **SPECIAL STORAGE CONDITIONS**

This veterinary product does not require any special storage conditions.

12. **SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Dispose of waste material in accordance with local requirements.

13. **THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only. To be supplied only on veterinary prescription.

14. **THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

15. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Ecuphar NV
Legeweg 157-i
B-8020 Oostkamp
Belgium

16. **MARKETING AUTHORISATION NUMBER(S)**

EU/2/08/088/004

17. **MANUFACTURER’S BATCH NUMBER**

Lot: {number}
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Acticam 5 mg/ml solution for injection for dogs and cats. Meloxicam.

2. QUANTITY OF THE ACTIVE SUBSTANCE(S)

3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES

10 ml.

4. ROUTE(S) OF ADMINISTRATION

Dogs: i.v. or s.c.
Cats: s.c.

5. WITHDRAWAL PERIOD(S)

6. BATCH NUMBER

Lot: {number}

7. EXPIRY DATE

EXP {month/year}
Shelf life after first opening the container: 28 days.

8. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.
1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Ecuphar NV
Legeweg 157-i
B-8020 Oostkamp
Belgium

2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Acticam 5 mg/ml solution for injection for dogs and cats.
Meloxicam.

3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

Meloxicam 5 mg/ml.
Ethanol anhydrous 150 mg/ml.

4. INDICATION(S)

Dogs:
Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders. Reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery.

Cats:
Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.

5. CONTRAINDICATIONS

Do not use in pregnant or lactating animals.
Do not use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.
Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
Do not use in animals less than 6 weeks of age nor in cats of less than 2 kg.

6. ADVERSE REACTIONS

Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure have occasionally been reported. In very rare cases elevated liver enzymes have been reported. In dogs, in very rare cases, haemorrhagic diarrhoea, haematemesia and gastrointestinal ulceration have been reported. In dogs, these side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal. In very rare cases anaphylactoid reactions may occur and should be treated symptomatically.
If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

7. TARGET SPECIES

Dogs and cats.

8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

Dogs: single administration of 0.2 mg meloxicam/kg body weight (i.e. 0.4 ml/10 kg).
Cats: single administration of 0.3 mg meloxicam/kg body weight (i.e. 0.06 ml/kg).

Dogs
Musculo-skeletal disorders: single subcutaneous injection.
Reduction of post-operative pain (over a period of 24 hours): single intravenous or subcutaneous injection before surgery, for example at the time of induction of anaesthesia.

Cats:
Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery: single subcutaneous injection before surgery, for example at the time of induction of anaesthesia.

Avoid introduction of contamination during use.

9. ADVICE ON CORRECT ADMINISTRATION

Particular care should be taken with regard to the accuracy of dosing.

10. WITHDRAWAL PERIOD(S)

Not applicable.

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.
This veterinary medicinal product does not require any special storage conditions.
Shelf-life after first opening the container: 28 days.
Do not use this veterinary medicinal product after the expiry date which is stated on the carton and the vial after EXP. The expiry date refers to the last day of that month.
12. SPECIAL WARNING(S)

For post-operative pain relief in cats, safety has only been documented after thiopental/halothane anaesthesia.

Special precautions for use in animals:

If side effects occur, treatment should be discontinued and the advice of a veterinarian should be sought.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity.
Any oral follow-up therapy using meloxicam or other NSAIDs should not be administered in cats, as appropriate dosage regimens for such follow-up treatments have not been established.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Accidental self-injection may give rise to pain. People with known hypersensitivity to meloxicam should avoid contact with the veterinary medicinal product.
In case of accidental self-injection, seek medical advice immediately and show this package insert or the label to the physician.

Pregnancy and lactation:

See section “Contraindications”.

Interaction with other medicinal products and other forms of interaction:

Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Acticam must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Concurrent administration of potential nephrotoxic drugs should be avoided. In animals at anaesthetic risk (e.g. aged animals) intravenous or subcutaneous fluid therapy during anaesthesia should be taken into consideration. When anaesthesia and NSAID are concomitantly administered, a risk for renal function cannot be excluded.
Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacokinetic properties of the products used previously.

Overdose (symptoms, emergency procedures, antidotes):

In the case of over dosage symptomatic treatment should be initiated.

Incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.
13. **SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

14. **DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

…

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/).

15. **OTHER INFORMATION**

Pack sizes:
Single 10 ml injection vial.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

**Belgique/Belgium**
Ecuphar NV
Legeweg 157-i
BE-8020 Oostkamp
Tel/Tel: + 32 (0)50 31 42 69
info@ecuphar.be

**Lietuva**
Ecuphar NV
Legeweg 157-i
BE-8020 Oostkamp
Tel: + 32 (0)50 31 42 69
info@ecuphar.be

**Република България**
Ecuphar NV
Legeweg 157-i
BE-8020 Oostkamp
Tel: + 32 (0)50 31 42 69
info@ecuphar.be

**Luxembourg/Luxemburg**
Ecuphar NV
Legeweg 157-i
BE-8020 Oostkamp
Tel/Tel: + 32 (0)50 31 42 69
info@ecuphar.be

**Česká republika**
Cymedica spol. s.r.o.
Pod Nádražím 308/24
CZ 268 01 Hořovice
Tel: + 420 311 706 211
info@cymedica.cz

**Magyarország**
Ecuphar NV
Legeweg 157-i
BE-8020 Oostkamp
Tel.: + 32 (0)50 31 42 69
info@ecuphar.be

**Danmark**
Ecuphar NV
Legeweg 157-i
BE-8020 Oostkamp
Tlf: + 32 (0)50 31 42 69
info@ecuphar.be

**Malta**
Ecuphar NV
Legeweg 157-i
BE-8020 Oostkamp
Tel: + 32 (0)50 31 42 69
info@ecuphar.be
Ísland
Ecuphar NV
Legeweg 157-i
BE-8020 Oostkamp
Sími: + 32 (0)50 31 42 69
info@ecuphar.be

Italia
Ecuphar Italia S.R.L.
Viale Francesco Restelli, 3/7
IT-20124 Milano
Tel: + 39 0282950604
info@ecuphar.it

Κύπρος
Ecuphar NV
Legeweg 157-i
BE-8020 Oostkamp
Τηλ: + 32 (0)50 31 42 69
info@ecuphar.be

Latvija
Ecuphar NV
Legeweg 157-i
BE-8020 Oostkamp
Tel: + 32 (0)50 31 42 69
info@ecuphar.be

Slovenská republika
Cymedica SK, spol. s r.o.
Družstevná 1415/8
SK-960 01 Zvolen
Tel: +421 455 400 040
info@cymedica.sk

Suomi/Finland
Ecuphar NV
Legeweg 157-i
BE-8020 Oostkamp
Puh/Tel: + 32 (0)50 31 42 69
info@ecuphar.be

Sverige
Ecuphar NV
Legeweg 157-i
BE-8020 Oostkamp
Tel: + 32 (0)50 31 42 69
info@ecuphar.be

United Kingdom
Ecuphar NV
Legeweg 157-i
BE-8020 Oostkamp
Tel: + 32 (0)50 31 42 69
info@ecuphar.be

Medicinal product no longer authorised